Delivery Order SPE2DB20D3101-SPE2DB25FRTF4
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 4, 2025, by the Defense Logistics Agency (DLA) for Dupixent 200 mg/1.14 ml pen auto-injectors. The contract is valued at $1,935.84 with a firm fixed price structure and an ultimate completion date of August 5, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $26,119.30 for Dupixent 300 mg/2 ml pen (2 ml) under a firm fixed price contract with the Defense Logistics Agency's Medical Supply Chain. The award was made on July 30, 2025, with an ultimate completion date of July 31, 2025, and represents a non-set-aside, competitively awarded contract. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at approximately $24,000 on August 25, 2025, by the Department of Defense Medical Supply Chain to supply Dupixent 300 mg/2 mL pen injectors. The contract is non-competitive, firm fixed-price, and carries an ultimate completion date of August 26, 2025, with performance occurring at the vendor's Conshohocken facility. This delivery order is executed under...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,144.72 by the Defense Logistics Agency on August 4, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL). This competitively awarded, firm fixed-price contract carries no set-aside designation and is scheduled for completion by August 5, 2025. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml pen injections on August 19, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order falls under AmerisourceBergen's comprehensive...
- The Defense Logistics Agency awarded a delivery order valued at $21,925.15 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price delivery order is non-competitive and carries no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery from its corporate office location. The award represents a child order under...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 22, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $18,961.13. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 25, 2025, and performance based in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRTF4Delivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency valued at approximately $50.9K for Dupixent 300 mg/2 ml pen injectors. The award, issued on August 21, 2025, with an ultimate completion date of August 22, 2025, was competitively awarded without set-aside restrictions under a firm fixed-price arrangement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9M and extending through December 2026, which serves as the primary pharmaceutical supply vehicle for federal military and healthcare systems. The DLA Medical Supply Chain relies on this IDC to source a comprehensive portfolio of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Dupixent, a specialized biologic medication, represents the type of specialty pharmaceutical that AmerisourceBergen delivers through its federal contracts to support the Defense Health Agency and other government healthcare entities. The company's extensive federal contract portfolio and demonstrated capability to meet competitive procurement requirements across multiple therapeutic domains position it as a critical vendor for federal medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $50.9k | 8/21/25 |